218 related articles for article (PubMed ID: 24940700)
1. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
[TBL] [Abstract][Full Text] [Related]
4. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
5. Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase--an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line.
Kalra S; Paul MK; Balaram H; Mukhopadhyay AK
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):7-14. PubMed ID: 17081813
[TBL] [Abstract][Full Text] [Related]
6. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
[TBL] [Abstract][Full Text] [Related]
7. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia.
Bostrom B; Erdmann G
Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):80-6. PubMed ID: 8447563
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
Lennard L; Welch JC; Lilleyman JS
Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
[TBL] [Abstract][Full Text] [Related]
10. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
[TBL] [Abstract][Full Text] [Related]
12. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
13. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
14. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
[TBL] [Abstract][Full Text] [Related]
15. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
17. A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
Hanff LM; Mathot RA; Smeets O; Postma DJ; Ramnarain S; Vermes A; Pieters R; Zwaan CM
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):653-62. PubMed ID: 24800919
[TBL] [Abstract][Full Text] [Related]
18. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
19. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
20. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
